Ann: Proteomics bolsters executive team - CCO and CFO appointed, page-80

So just to clarify Juju, you are staying strong on your word that I am paid to downramp and manipulate the stockprice?

Why do you feel the need to denigrate me by using terms like "numpty" and "duck". You claim yourself to be a realist, but as soon as someone tries to engage in a forum with a differing view, and asks questions which you are uncomfortable with, then they are a downramping numpty duck and anything they have to say thereafter is invalid. To me, that is not a realist. To me, that is someone with poor investment accument and poor risk management.

You claim to be a successful senior manager yet you behave like this? No successful senior manager rejects a differing view. A seasoned investor would also know not to associate stock price with progress and management (not in the short term, 1-2 years anyways) yet that appears to be what you have done. If the stockprice always reflected a company's fundamentals and risk profile at all times, then there would be no way to get one up on the market as the SP would always be "fairly priced". In fact, the stock prices rarely follow fundamentals in the short term, which can lead to buying opportunities (if SP undervalued compated to fundamentals), or overvalued (if SP overvalued compared to fundamentals). It is clear to me you think that based on PIQ's current fundamentals and risk profile that the SP is undervalued or at least fairly valued. Care to use some of your senior management skills and show us why? Would your view change if PromarkerD flops in the USA?